Autopsy report · NCT04658849

Insulin Resistance Following ADT for Prostate CA

“End of grant funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

St. Louis University

Sponsor type

University, hospital or other

Conditions

Insulin Resistance; Prostate Cancer

Interventions

Pioglitazone 30 Mg Oral Tablet; Pioglitazone placebo tablet

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction
  “End of funding” (89% match in meaning)
• Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)
  “funding ending” (84% match in meaning)
• Effect of Concentrating Endogenous Stromal Cells in the Fat Graft
  “Funding ended” (75% match in meaning)
• Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
  “Funding ended prematurely” (73% match in meaning)
• Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury
  “Funding Termination” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.